Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Both manufacturing facilities are based out of Benguluru, India
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
QIAGEN has started its cloud transformation journey with the firm belief that cloud computing can be a key enabler of future business growth
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
Gilman will be responsible for all business development and portfolio strategy efforts globally.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Subscribe To Our Newsletter & Stay Updated
